279 related articles for article (PubMed ID: 31681976)
1. Effects of levothyroxine therapy on bone mineral density and bone turnover markers in premenopausal women with thyroid cancer after thyroidectomy.
Bin-Hong D; Fu-Man D; Yu L; Xu-Ping W; Bing-Feng B
Endokrynol Pol; 2020; 71(1):15-20. PubMed ID: 31681976
[TBL] [Abstract][Full Text] [Related]
2. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women.
Baqi L; Payer J; Killinger Z; Hruzikova P; Cierny D; Susienkova K; Langer P
Endocr Regul; 2010 Apr; 44(2):57-63. PubMed ID: 20429634
[TBL] [Abstract][Full Text] [Related]
3. Effects of TSH suppressive therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with differentiated thyroid cancer in Northeast China: a prospective controlled cohort study.
Wang S; Wang Y; Zhu L; He L; Lv M; Zhang H; Wang H; Zhang F; Lai Y; Li Y; Shan Z; Teng W
Endocrine; 2023 Jan; 79(1):113-124. PubMed ID: 36089636
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
Guo CY; Weetman AP; Eastell R
Clin Endocrinol (Oxf); 1997 Mar; 46(3):301-7. PubMed ID: 9156039
[TBL] [Abstract][Full Text] [Related]
5. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study.
Appetecchia M
Horm Res; 2005; 64(6):293-8. PubMed ID: 16269872
[TBL] [Abstract][Full Text] [Related]
6. The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women.
Sajjinanont T; Rajchadara S; Sriassawaamorn N; Panichkul S
J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S71-6. PubMed ID: 16858944
[TBL] [Abstract][Full Text] [Related]
7. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.
Hawkins Carranza F; Guadalix Iglesias S; Luisa De Mingo Domínguez M; Martín-Arriscado Arroba C; López Álvarez B; Allo Miguel G; Martínez Díaz-Guerra G
Cancer Med; 2020 Aug; 9(16):5746-5755. PubMed ID: 32583973
[TBL] [Abstract][Full Text] [Related]
8. The level of TSH appeared favourable in maintaining bone mineral density in postmenopausal women.
Baqi L; Payer J; Killinger Z; Susienkova K; Jackuliak P; Cierny D; Langer P
Endocr Regul; 2010 Jan; 44(1):9-15. PubMed ID: 20151763
[TBL] [Abstract][Full Text] [Related]
9. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women.
Marcocci C; Golia F; Bruno-Bossio G; Vignali E; Pinchera A
J Clin Endocrinol Metab; 1994 Apr; 78(4):818-23. PubMed ID: 8157704
[TBL] [Abstract][Full Text] [Related]
10. Bone turnover markers in patients with differentiated thyroid carcinoma after levothyroxine withdrawal.
Gao YC; Gu Q; Liu QP; Ge WL; Lu HK
Clin Lab; 2010; 56(3-4):87-93. PubMed ID: 20476639
[TBL] [Abstract][Full Text] [Related]
11. Effects of levothyroxine on bone mineral density, muscle force, and bone turnover markers: a cohort study.
Schneider R; Schneider M; Reiners C; Schneider P
J Clin Endocrinol Metab; 2012 Nov; 97(11):3926-34. PubMed ID: 22977269
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
13. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.
Jódar E; Begoña López M; García L; Rigopoulou D; Martínez G; Hawkins F
Osteoporos Int; 1998; 8(4):311-6. PubMed ID: 10024900
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
[TBL] [Abstract][Full Text] [Related]
15. Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy.
Toivonen J; Tähtelä R; Laitinen K; Risteli J; Välimäki MJ
Eur J Endocrinol; 1998 Jun; 138(6):667-73. PubMed ID: 9678534
[TBL] [Abstract][Full Text] [Related]
16. Trabecular bone score in women with differentiated thyroid cancer on long-term TSH-suppressive therapy.
Sousa BÉCA; Silva BC; de Oliveira Guidotti T; Pires MC; Soares MMS; Kakehasi AM
J Endocrinol Invest; 2021 Oct; 44(10):2295-2305. PubMed ID: 33730348
[TBL] [Abstract][Full Text] [Related]
17. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
[TBL] [Abstract][Full Text] [Related]
18. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
Sijanovic S; Karner I
Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-1 is associated with bone formation markers, PTH and bone mineral density in healthy premenopausal women.
Adami S; Zivelonghi A; Braga V; Fracassi E; Gatti D; Rossini M; Ulivieri FM; Viapiana O
Bone; 2010 Jan; 46(1):244-7. PubMed ID: 19853071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
